Denali Therapeutics (DNLI) Q3 2026 earnings review
Denali's first drug beats its sales plan, but cash burn stays high
Denali Therapeutics, a biotechnology company developing drugs that cross the blood-brain barrier, grew sales of its first approved medicine much faster than its own plan while its research spending kept underlying losses high. Net product sales of Hunter syndrome therapy AVLAYAH reached $18 million in its second full quarter on the market, beating the $10 million to $12 million outlook as commercial insurance coverage passed 70%. Chief executive Ryan Watts credited strong demand from families and doctors, and the company set a fourth-quarter sales outlook of $30 million to $32 million.
| AVLAYAH product revenue | $17.8M $3.6M last quarter (plan was $10–12M) |
|---|---|
| Q4 product revenue outlook | $30.0–32.0M middle of the range: +74% from Q3 |
| Net loss excluding voucher sale | $123.9M by our math ($70.1M profit as reported) |
| Cash and marketable securities | $1.01B includes $194M one-time voucher gain |
⚖️ Verdict: 🟢 Bullish
The story got better because rapid insurance approvals and a permanent billing code turned early patient interest into a $124 million annualised sales run rate at the middle of the fourth-quarter plan. The drugmaker also finished enrolling all 65 patients in AVLAYAH's confirmatory trial and completed the primary treatment period for its second rare-disease drug ahead of a planned 2027 approval filing. One caution: the $70 million headline profit came entirely from a $194 million one-time regulatory voucher sale, hiding $127 million in quarterly cash burn by our math.
The question now is whether AVLAYAH's rapid climb reflects steady long-term adoption or a one-time wave of pre-identified families from a small U.S. pool of about 375 eligible children. Because management does not disclose patient counts, bulls see a smooth ramp toward peak sales while sceptics see front-loaded demand that will slow in 2027. Full-year 2027 sales plans or patient disclosures early next year will settle the debate.
🐂 Bull Case
AVLAYAH Sales Topped Plan as Coverage Expanded
AVLAYAH is Denali's newly approved enzyme replacement therapy for Hunter syndrome, a rare genetic disorder that damages the body and brain. In its second full quarter on the market, the medicine generated $17.8 million in net product sales, beating the company's $10.0 million to $12.0 million plan by 62% at the middle of the range.
- Fourth-quarter product sales outlook: $30.0 million to $32.0 million, up 74% from this quarter at the middle of the range
- U.S. commercial insurance coverage: over 70% of covered lives, up from over 50% last quarter
- State Medicaid coverage: 20 states have published coverage, up from 14 last quarter
- Reimbursement billing code: permanent J-code took effect on October 1, "streamlining billing and reimbursement for treatment centers"
Chief executive Ryan Watts said "the results this quarter reflect" that the drug is helping children, and the fourth-quarter outlook points to an annual sales pace above $120 million. Still, sceptics worry that early revenue reflects pent-up demand from a small pool of about 375 eligible U.S. children, because by our math the outlook adds $13.2 million in new quarterly sales compared with $14.2 million added this quarter.
What to watch: fourth-quarter net product sales and whether management gives a full-year 2027 sales outlook in January. A 2027 plan showing steady quarterly additions would prove the launch has room to grow beyond the initial wave of families.
Confirmatory Trial Enrolled and Next Drug Nears Filing
Denali uses its TransportVehicle technology to carry medicines across the blood-brain barrier into the brain. Because the U.S. regulator approved AVLAYAH for children under an accelerated pathway, keeping the drug on the market and expanding its label to adults depends on the Phase 2/3 COMPASS confirmatory trial.
This quarter, the biotech group finished enrolling Cohort B of COMPASS, reaching 65 total patients across Cohorts A and B for "supporting future global regulatory submissions". Meanwhile, its second brain-penetrating enzyme therapy, zafinofusp alfa for Sanfilippo syndrome type A, finished the primary treatment period for all 20 patients in its Phase 1/2 trial.
Finishing enrollment removes recruitment delays for AVLAYAH's confirmatory test, though Denali now expects COMPASS results in the first half of 2028 rather than at the end of 2027. For zafinofusp alfa, completing the primary treatment window keeps the company on schedule to file for accelerated U.S. approval in 2027.
What to watch: additional Phase 1/2 data for zafinofusp alfa at a medical meeting in the first quarter of 2027. Consistent drops in spinal fluid disease markers across all 20 patients would support the 2027 approval filing.
🐻 Bear Case
Voucher Sale Masked $127 Million of Cash Burn
Denali reported $70.1 million in third-quarter net income and $1.0 billion in cash and marketable securities. However, that profit came from a one-time $194.0 million net gain on the sale of a Priority Review Voucher, a transferable regulatory speed-pass the company received when AVLAYAH won approval.
- Net loss excluding the voucher sale: $123.9 million by our math, compared with a $126.9 million loss a year ago
- Loss from operations: $126.8 million, down 3% from $130.5 million last quarter
- Cash and marketable securities: $1,007.6 million on September 30, down $127.4 million from the $1,135.0 million pro forma balance after the voucher sale closed in July
Even with AVLAYAH sales rising, research and overhead costs rose 5.2% from a year ago to $144.5 million, leaving a quarterly cash burn above $120 million. In addition, non-cash interest on its funding deal with Royalty Pharma added $4.5 million to liabilities this quarter and cut net interest income to $2.9 million from $10.5 million a year ago.
What to watch: fourth-quarter operating expenses and ending cash balances in the annual report. If rising AVLAYAH revenue does not shrink quarterly cash use below $100 million in 2027, Denali may need to raise more money before its pipeline matures.
Five Brain-Delivery Drugs Face Clinical Tests in 2027
Watts said the early commercial success of AVLAYAH "show what is possible for our TransportVehicle portfolio" across wider brain diseases. To prove the platform works beyond rare pediatric enzyme disorders, Denali is running clinical trials in Alzheimer's disease, frontotemporal dementia (FTD-GRN), Pompe disease, and Parkinson's disease.
- DNL593 for FTD-GRN: granted FDA Orphan Drug Designation in August; Phase 1/2 data from 40 patients expected in the first half of 2027 after slipping from late 2026
- DNL628 (tau target) and DNL921 (amyloid target) for Alzheimer's disease: Phase 1b biomarker data expected in the first half of 2027 and proof-of-concept data in 2027
- DNL151 for Parkinson's disease: Phase 2a BEACON data in genetic mutation carriers expected in the first half of 2027, following the failure of the wider LUMA study in May
This creates a clustered clinical hurdle in 2027, and previous setbacks show the risk. Partner Takeda walked away from DNL593 in April before Denali delayed its readout, and partner Biogen halted the broader Parkinson's trial for DNL151 after it missed its goals.
What to watch: first-half 2027 clinical readouts for DNL593 in dementia and DNL628 in Alzheimer's disease. Weak biomarker changes in either trial would show that crossing the blood-brain barrier in enzyme replacement does not guarantee success in adult neurodegeneration.
Risks This Quarter Didn't Answer
Three standing commercial and competitive concerns received no direct numbers in the third-quarter earnings release.
- Active patient counts: management again gave no figure for patients on AVLAYAH or prescription start forms, making it impossible to separate new patient starts from weight-based dose increases.
- Distributor stocking and customer concentration: accounts receivable jumped to $18.9 million, or 106% of quarterly sales by our math, and the release did not state how much revenue came from specialty distributor inventory building.
- Rival Hunter syndrome therapies: the release gave no update on competing blood-brain barrier or gene-therapy trials such as JCR Pharmaceuticals' Phase 3 program.
👓 Other Themes
Pre-Launch Inventory Kept Product Costs Near Zero
Denali recorded just $0.2 million in cost of goods sold on $17.8 million of product sales, resulting in a 98.9% gross margin by our math. "Because manufacturing costs incurred prior to FDA approval of AVLAYAH were expensed as research and development, cost of goods sold during the initial commercialization period reflects a lower average per-unit cost as previously expensed inventory is sold," the company explained, while capitalised inventory on the balance sheet rose from $4.1 million to $26.3 million as it builds full-cost stock for 2027.
💲 Other KPIs
Spending on research and overhead rose 4.5% from a year ago and 7.7% from last quarter. Research and development rose $4.1 million from last year to $106.1 million on TransportVehicle trials, while selling and administrative costs rose $2.0 million to $37.5 million to back the AVLAYAH launch.
Uncollected bills from customers rose nearly fivefold from $3.9 million in the second quarter as AVLAYAH sales ramped up. By our math, receivables at the end of September equalled 106% of third-quarter product sales, showing that most third-quarter billings had not yet turned into cash by quarter-end.
Weighted-average diluted shares rose 11.4% from 172.4 million a year ago. Basic shares grew 9.3% to 188.4 million following last December's stock offering, and reporting positive net income from the voucher sale added another 3.7 million diluted shares from employee options and warrants.
🔮 Guidance
New. The drugmaker expects fourth-quarter product sales of $31.0 million at the middle of the range, up 74% from the third quarter's $17.8 million. By our math, that brings full-year 2026 product revenue to $52.4 million and implies $13.2 million of sequential quarterly growth, compared with $14.2 million added in the third quarter.
❓ Key Questions
How many patients are currently receiving AVLAYAH infusions?
Denali has reported two quarters of commercial revenue without disclosing patient counts or prescription start forms. Without knowing how many of the roughly 375 eligible U.S. children have started therapy, investors cannot tell how close the drug is to saturating its initial market.
How much of Q3 revenue came from distributor inventory stocking?
Accounts receivable ended the quarter at $18.9 million, exceeding the $17.8 million of revenue booked in the period, and balance-sheet inventory jumped to $26.3 million. Management has not disclosed how much product sits in specialty distributor warehouses versus being infused into patients.
Why did COMPASS confirmatory data move to the first half of 2028?
Last quarter, medical chief Peter Chin said the COMPASS study was set to end at the end of 2027. Even though enrollment of all 65 patients finished this quarter, the release now guides for data in the first half of 2028.
What will AVLAYAH gross margin be once pre-launch inventory runs out?
Cost of goods sold was just 1.1% of revenue this quarter because initial batches were expensed to research before approval. With capitalised inventory rising by $22.1 million this quarter, fully costed batches will enter cost of goods sold in early 2027.